Technical Analysis for VRCA - Verrica Pharmaceuticals Inc.

Grade	Last Price	% Change	Price Change
	8.8	-3.51%	-0.32

VRCA closed down 3.51 percent on Friday, May 17, 2019, on 32 percent of normal volume.

ADX	Long-Term	Intermediate-Term	Short-Term
Strong	Down	Down	Down
See historical VRCA trend table...

Date	Alert Name	Type	% Chg
May 17	MACD Bearish Signal Line Cross	Bearish	0.00%
May 17	Bollinger Band Squeeze	Range Contraction	0.00%
May 17	BB Squeeze + Lower Band Touch	Range Contraction	0.00%
May 17	BB Squeeze Started	Range Contraction	0.00%
May 17	Below Lower BB	Weakness	0.00%
May 17	Down 3 Days in a Row	Weakness	0.00%
May 17	Lower Bollinger Band Touch	Weakness	0.00%
May 16	New Downtrend	Bearish	-3.51%
May 16	Non-ADX 1,2,3,4 Bearish	Bearish Swing Setup	-3.51%
May 16	Narrow Range Bar	Range Contraction	-3.51%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Verrica is a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs. The company’s lead product candidate, VP-102, is currently being evaluated in two Phase 3 clinical trials for the treatment of molluscum and in a Phase 2 clinical trial for the treatment of common warts.
Health Pharmaceutical Pharmaceutical Industry Medication Pharmaceutical Products Clinical Trial Common Warts Skin Diseases Treatment Of Skin Diseases

Indicator	Bull Case	Neutral / Hold	Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary:	Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

Date	Title
May 7	Verrica Pharmaceuticals misses by $0.02
May 7	Verrica Pharmaceuticals Reports First Quarter 2019 Financial Results
May 1	Verrica Pharmaceuticals Announces Participation in Upcoming Investor Conferences
Apr 18	Verrica Pharma axes operating chief
Mar 7	Verrica Pharmaceuticals reports Q4 results
Mar 7	Verrica Reports Fourth Quarter and Full Year 2018 Financial Results
Mar 4	Verrica Pharma up 7% on positive lead candidate data
Mar 2	Verrica Pharmaceuticals Presents Positive Results from Two Phase 3 Clinical Trials of VP-102 in Late-Breaking Oral Presentation at the 2019 American Academy of Dermatology Meeting
Feb 27	Verrica Pharmaceuticals Announces Participation in the Cowen and Company 39th Annual Healthcare Conference
Feb 22	The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs

Pivot Point Level	Traditional / Classic	Fibonacci	Demark	Woodie	Camarilla
Resistance 4 (R4)					9.72
Resistance 3 (R3)	9.79	9.55			9.56
Resistance 2 (R2)	9.55	9.32		9.52	9.51
Resistance 1 (R1)	9.18	9.18	9.06	9.11	9.46
Pivot Point	8.94	8.94	8.89	8.91	8.94
Support 1 (S1)	8.57	8.71	8.45	8.50	8.14
Support 2 (S2)	8.33	8.57		8.30	8.09
Support 3 (S3)	7.96	8.33			8.04
Support 4 (S4)					7.89